J&J Says Its Single Dose Protects Against Breakthrough COVID-19 for Up to 6 Months

By Reuters Staff

January 10, 2022

(Reuters) - Johnson & Johnson said on Thursday that a real-world study showed its single-shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.

The study, sponsored by the vaccine developer and posted on medRxiv ahead of peer review, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered, the company said in a press release.

J&J said protection against infection from its single-dose adenoviral-vector vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose mRNA vaccines from rivals Pfizer Inc and BioNTech as well as Moderna.

No waning of protection was found for ICU admissions for all the three vaccines, J&J said.

The company said the study was carried out by collecting claims and laboratory data covering 168 million people.

SOURCE: https://bit.ly/3qQRDt4 medRxiv, online January 6, 2021.